Three Ways Sponsors Qualify Clinical Trial Vendors: In-House, Audit Firms, or a Centralized Qualification Model

Every Sponsor running a clinical trial carries the same obligation under ICH E6(R3): to assess a Vendor’s suitability before work begins, to document the basis for the decision, and to oversee the relationship on a risk-proportionate basis for the duration of the study. The guideline is specific about the outcome, but silent on the method. How a Sponsor organizes the work of qualification is left for the Sponsor to decide, with the most common approaches carrying substantially different costs in time, budget, and internal capacity. 

This article describes three approaches to Vendor qualification as they operate in practice: where each performs well, where they can fall short, and how to choose the method that works best for your organization.  

What does ICH E6(R3) require a Sponsor to do? 

Regardless of approach, qualification consists of the same core activities: collecting information on a Vendor’s quality management system, capabilities, and compliance history; evaluating the information against current regulatory expectations; documenting a defensible decision; and reassessing on a defined schedule. Who issues the questionnaire, who conducts the audit, and who maintains the file are questions of approach rather than requirement; ICH E6(R3) Section 3.6.6 permits sponsors to transfer trial-related activities—including auditing—to service providers, provided that qualified individuals perform the work (Section 3.4). As long as the sponsor retains regulatory responsibility and accountability, delegating auditing activities remains a viable option. 

Approach 1: Build the qualification function in-house 

Under the traditional model, the Sponsor’s own Quality team maintains its qualification questionnaires, issues them to each prospective Vendor, reviews the responses, determines whether an on-site or remote audit is warranted, and conducts the audit with internal auditors.  

Where it works 

Large Sponsors with an established Quality organization, a stable roster of Vendors, strong tech infrastructure to manage Vendor communication and documentation, and the headcount to keep questionnaires current as regulations evolve. Internal ownership and control of every step in the qualification process is the principal advantage for Sponsors, and for some organizations this control of the process is non-negotiable. 

Where it falls short 

Capacity and repetition. Each new Vendor relationship restarts the process from the beginning, and the same Vendor is being qualified in parallel by every other Sponsor it serves. Timelines lengthen as Vendors manage competing requests sent with different tools, and questionnaires fall out of alignment with current guidance unless a dedicated resource owns their maintenance. For an emerging biotech with a single Quality lead, qualification under the in-house model frequently becomes the primary constraint on study start-up and can introduce compliance risks if not properly staffed. 

Approach 2: Commission audits from a third-party firm 

In the outsourced-audit model, the Sponsor contracts the remote or on-site qualification assessment to a consulting or audit firm. The firm conducts the assessment and delivers a report to its client. The Sponsor reviews the report, records the qualification and selection decision, and maintains the documentation. 

Where it works 

Sponsors who have a fluctuating audit volume or require qualification audits in emerging Vendor categories can hire specialized external expertise without adding permanent headcount. Costs from third-party firms are predictable. 

Where it falls short 

Cost and scheduling. Sponsors pay full market rates for qualifications that have, in substance, already been performed in a nearly identical fashion for other Sponsors. Scheduling remains subject to the Vendor’s audit calendar, continuing the issue of long qualification timelines. (While Sponsors can hire external auditors, Vendors’ internal capacity determines how many audits they are able to host each year.)  

Approach 3: Use a centralized, shared qualification model 

In a centralized model, an independent qualification organization assesses each Vendor once per year using rigorous standards aligned with current regulations and, with the Vendor’s consent, makes the completed questionnaires and audit reports available to participating Sponsors. Sponsors request a qualification record rather than initiating an audit, and Vendors host one independent assessment annually in place of one per client. Diligent Pharma operates on this model and, for GCP Vendor qualification, is the only centralized program of its kind that we are aware of. 

Where it works 

Sponsors that qualify Vendors frequently on compressed timelines with fixed team bandwidth, and that are prepared to leverage an independent, expert-led assessment as the evidentiary basis for their own documented decision. Qualification timelines move from months to days, audit costs and SME burden are reduced significantly, and internal processes become aligned with risk-based regulatory standards for qualification. Lean teams benefit from immediate access to data and infrastructure for compliant, scalable qualification rather than having to increase headcount.   

Where it has limits 

Coverage. A shared model is only as useful as the Vendors already assessed within it, so a Sponsor engaging a highly specialized or newly formed Vendor may still require a supplemental assessment. However, as more Sponsors adopt the centralized model, it will in turn grow the library of qualification data available and boost coverage.  

How do Vendor directories and marketplaces fit in? 

Vendor databases and marketplaces address a different problem. They help a Sponsor discover Vendors beyond their current network and identify which companies operate in a given category. A directory listing establishes that a Vendor offers a service, but it does not establish whether the Vendor’s quality systems and experience meet the standard a particular trial requires.  

Discovery and qualification are therefore separate steps that, when performed well, reinforce stronger selection decisions; Sponsors who leverage discovery platforms instead of returning to the same list of Vendors can uncover partners better suited to their needs. Platforms like Diligent, which pair robust Vendor discovery tools with a centralized qualification model, allow Sponsors to perform both steps within a single platform. 

How should a Sponsor choose? 

Several questions can be asked to make an informed decision: 

• How many new Vendor relationships will be qualified in the next twelve months? Below a handful, in-house or one-off audits may be manageable. Above that number, repetition becomes the dominant cost. 

• Does the sponsor have the internal capacity to manage their audit burden while adhering to strict trial timelines? 

• Who owns keeping the qualification questionnaires aligned to ICH E6(R3) and evolving guidance, and how much of their time does it consume? 

• When a study is ready to start, how long does qualification currently add to the timeline, and what does each week of delay cost the program? 

• For the categories and Vendors qualified most often, does their recent qualification data already exist within a centralized platform? 

• For specialized categories, does the Sponsor’s internal teams have the correct SMEs to ensure the correct questions are being asked? 

Where Diligent fits 

Diligent Pharma’s platform is built on the centralized model. Sponsors search a database of Vendors by category and request the complete record: completed questionnaires that cite relevant regulations in each question; the independent audit report; and where applicable, SME-led risk scoring based on Sponsor requirements. Behind each record is a single annual assessment conducted by Diligent’s auditors and comprehensive questionnaires mapped to current regulations and GxP standards, released to participating Sponsors with full Vendor consent. Most Vendors are qualified in days rather than months, and Sponsors report an average 60% reduction in qualification costs in addition to stronger compliance with ICH E6(R3).  

If you are weighing these approaches for an upcoming study, book a demo to see how the centralized model works in practice.